Esomeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+ -ATPase in the gastric parietal cell. It blocks the final step in acid production thus reducing gastric acidity.

Clinical Advantage of Esolok MUPS Tablet:

1. Ensures greater bioavailability 2. Ensures Tmax & Cmax very fast 3.Once daily dose 4. No fluctuation in plasma concentration of drug 5. Ensures reduction of esophageal residence time 6. Ensure less possibility of dose dumping 7. Ensures less chance of localized irritation 8. Gives efficacy very fast & effective for long time.

Pharmacodynamic Advantage:

Pellets of MUPS tablet quickly transfer from stomach to intestine as a result absorption occur very fast. Due to small size pellets it covers largest area and maximum absorption occurs in intestine

• For the healing of erosive esophagitis
• For the maintenance of healing of erosive esophagitis
• For symptomatic gastroesophageal reflux disease
• For the risk reduction of NSAID induced gastric ulcers
• For the eradication of Helicobacter pylori in combination with Amoxicillin and Clarithromycin

For Adults from age 18 years-

Adolescents aged 12 – 17 years-

*Esomeprazole MUPS Tablet is not recommended for children under 12 years of age

Method of Taking Tablet:

This tablet can shallow before or after meal.

Esomeprazole MUPS is contraindicated in those patients who have known hypersensitivity to any component of the formulation of Esomeprazole. When used for H. Pylori eradication the contraindication of Amoxicillin and Clarithromycin should be followed.

Exclude the possibility of malignancy when gastric ulcer is suspected and before treatment for dyspepsia. When using in combination with antibiotic refer to the prescribing information of the respective antibiotics. For patient with severe liver impairment, a dose of 20 mg of esomeprazole should not be exceeded.

Headache, abdominal pain, diarrhea, flatulence, nausea or vomiting etc.

Manufacturer advices caution and there is no information available. It is not known whether Esomeprazole is excreted in breast milk or not.

Esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability such as Ketoconazole, Iron Salts and Digoxin.

A single oral dose of Esomeprazole at 510 mg/kg (about 103 times the human dose on a body surface area basis), has been lethal to rats. The major signs of acute toxicity are reduced motor activity, changes in respiratory frequency, tremor, ataxia, and intermittent clonic convulsions. There have been no reports of overdose with Esomeprazole. No specific antidote for Esomeprazole is known. Since Esomeprazole is extensively protein bound, it is not expected to be removed by dialysis. In the event of overdosage, treatment should be symptomatic and supportive. As with the management of any overdose, the possibility of multiple drug ingestion should be considered.

Store in a cool (below 30° C) and dry place, protect from light. Keep out of reach of children.

Esolok MUPS 20 Tablet: Each box contains 5x10 MUPS tablets in Alu-Alu blister pack.

Esolok MUPS 40 Tablet: Each box contains 3x10 MUPS tablets in Alu-Alu blister pack.